Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionProfund Advisors Llc
Latest Disclosed Ownership23,137 shares
Latest Disclosed Value $ 10,331,596
Profund Advisors Llc reports 19.71% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 24, 2026 - Profund Advisors Llc filed a 13F-HR form disclosing ownership of 23,137 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $10,331,596 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 28,818 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -19.71% during the quarter. The current value of the position is $10,220,538 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,137 -5,681 -19.71 10,332 -20.92 0.3793
2026-02-06 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,818 2,423 9.18 13,065 26.38 0.3970
2025-11-06 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 26,395 -958 -3.50 10,337 -15.11 0.3360
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,353 2,682 10.87 12,178 1.81 0.4384
2025-05-08 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 24,671 -3,903 -13.66 11,961 3.95 0.5197
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,574 654 2.34 11,507 -11.39 0.4201
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 27,920 -1,626 -5.50 12,985 -6.23 0.4912
2024-08-13 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,546 3,194 12.12 13,849 25.72 0.5135
2024-05-08 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,352 -1,730 -6.16 11,015 -3.60 0.4289
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,082 3,495 14.21 11,426 33.65 0.4908
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,587 4,653 23.34 8,550 21.88 0.4727
2023-08-10 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 19,934 967 5.10 7,015 17.39 0.3763
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,967 -22,299 -54.04 5,976 -49.86 0.3692
2023-02-02 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 41,266 -18 -0.04 11,917 -0.31 0.7733
2022-11-07 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 41,284 -2,018 -4.66 11,953 -2.04 0.8599
2022-08-01 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,302 -5,796 -11.80 12,202 -4.77 0.7749
2022-05-10 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 49,098 -9,510 -16.23 12,813 -0.44 0.5380
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 58,608 -8,612 -12.81 12,870 5.55 0.4208
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 67,220 37 0.06 12,193 -9.99 0.4109
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 67,183 -2,206 -3.18 13,547 -9.15 0.4550
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,389 -1,990 -2.79 14,911 -11.61 0.5732
2021-02-09 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 71,379 5,230 7.91 16,870 -6.28 0.7372
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 66,149 -8,501 -11.39 18,000 -16.94 0.9263
2020-08-03 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 74,650 9,783 15.08 21,672 40.41 1.2059
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 64,867 -21,092 -24.54 15,435 -17.99 1.1591
2020-02-18 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 85,959 8,698 11.26 18,821 43.78 0.8195
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 77,261 -4,059 -4.99 13,090 -12.22 0.6619
2019-08-13 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 81,320 -6,390 -7.29 14,912 -7.57 0.7070
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 87,710 1,342 1.55 16,134 12.74 0.7757
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 86,368 -20,840 -19.44 14,311 -30.74 0.8851
2018-11-13 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 107,208 9,424 9.64 20,663 24.33 0.7838
2018-08-13 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 97,784 -4,648 -4.54 16,619 -0.45 0.6639
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 102,432 -7,484 -6.81 16,694 1.35 0.6646
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 109,916 -11,097 -9.17 16,472 -10.47 0.6350
2017-11-13 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 121,013 9,680 8.69 18,399 28.24 0.7659
2017-08-11 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 111,333 -6,177 -5.26 14,347 11.65 0.6501
2017-04-25 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 117,510 -7,989 -6.37 12,850 38.98 0.5743
2017-02-13 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 125,499 -16,592 -11.68 9,246 -25.39 0.4257
2016-11-10 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 142,091 -5,790 -3.92 12,392 -2.59 0.5896
2016-08-12 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 147,881 -6,508 -4.22 12,721 3.66 0.6192
2016-05-06 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 154,389 -34,724 -18.36 12,272 -48.43 0.6360
2016-02-05 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 189,113 1,006 0.53 23,796 21.48 1.1292
2015-11-06 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 188,107 -10,171 -5.13 19,589 -19.99 1.1163
2015-08-11 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 198,278 -891 -0.45 24,483 4.20 1.0137
2015-05-08 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 199,169 199,169 0.00 23,496 0.9140
2015-01-30 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -168,126 -100.00 0 -100.00
2014-11-06 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 168,126 13,893 9.01 18,882 29.30 0.8844
2014-08-08 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 154,233 -38,354 -19.92 14,603 7.22 0.6404
2014-05-07 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 192,587 34,251 21.63 13,620 15.78 0.6190
2014-02-04 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 158,336 31,950 25.28 11,764 22.76 0.5272
2013-11-07 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 126,386 -8,093 -6.02 9,583 -10.78 0.5087
2013-07-25 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 134,479 134,479 10,741 0.7590
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.